Abstract
Dihydropyrimidine dehydrogenase (EC 1.3.1.2, DPD) is the initial rate-limiting enzyme in pyrimidine catabolism, which catalyzes the following reaction.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
T. W. Traut, and S. Loechel, Pyrimidine catabolism: individual characterization of the three sequential enzymes with a new assay, Biochemistry 23:2533–2539 (1984).
F. Zafra, M.C. Aragon, F. Valdiviesco, and C. Gimenez, ß-Alanine transport into plasma membrane vesicles derived from rat brain synaptosomes, Neurochem. Res. 9: 695–707 (1984).
R.B. Diasio and B.E. Harris, Clinical pharmacology of 5-fluorouracil, Clin. Pharmacokinet. 16: 215–237, 1989.
G.C. Daher, B. E. Harris, and R.B. Diasio, Metabolism of pyrimidine analogues and their nucleosides, Pharmacol. Ther. 48:189–222 (1990).
G.D. Heggie, J.-P. Sommadossi, D.S. Cross, W.J. Huster, and R.B. Diasio, Clinical Pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile, Cancer Res. 47:2203–2206 (1987).
B.E. Harris, R. Song, S.-J. Soong, and R.B. Diasio, Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion, Cancer Res. 50:197–201 (1990).
R.A. Fleming, G. Milano, A. Thyss, M.-C. Etienne, N. Renee, M. Schneider, and F. Demard, Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients, Cancer Res. 52: 2899–2902 (1992).
R. Zhang, Z. Lu, T. Liu, S.-J. Soong, and R.B. Diasio, Relationship between circadian-dependent toxicity of 5-fluorodeoxyuridine and circadian rhythms of pyrimidine enzymes; Possible relevance to fluoropyrimidine chemotherapy, Cancer Res. 53: 2816–2822 (1993).
M. Tuchman, J.S. Stoeckeler, D.T. Kiang, R.F. O’Dea, M.L. Rammaraine, and B.L. Mirkin, Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity, New Engl. J. Med. 313:245–249 (1985).
R.B. Diasio, T.L. Beavers, and J.T. Carpenter, Familial deficiency of dihydropyrimidine dehydrogenase, J. Clin. Invest. 81:47–51 (1988).
B.E. Harris, J.T. Carpenter, and R.B. Diasio, Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency: a potentially more common pharmacogenetic syndrome, Cancer 68: 499–501 (1991).
A.P. Lyss, R.C. Lilenbaum, B.E. Harries, and R.B. Diasio, Severe 5-fluorouracil toxicity in a patient with decreased dihydropyrimidine dehydrogenase activity, Cancer Invest. 11: 239–240 (1993).
Z. Lu, R. Zhang, R.B. Diasio, Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy, Cancer Res. 53: 5433–5438 (1993).
P. Houyau, C. Gay, E. Chatelut, P. Canal, H. Roche, and G. Milano, Severe fluorouracil toxicity in a patient with dihydropyrimidine dehydrogenase deficiency, J. Nat. Cancer Inst. 85: 1602–1603 (1993).
K. Ward, M.J. Henderson, H.A. Simmonds, J.A. Duley, and P.M. Davies, Dihydropyrimidinuria presenting in childhood with severe developmental retardation, in: “Molecular Genetics, Biochemistry and Clinical Aspects of Inherited Disorders of Purine and Pyrimidine Metabolism”, U. Gresser, ed., pp. 165–167, Springer-Verlag, Berlin Heidelberg (1993).
M. Brocksted, C. Jakobs, L.M.E. Smith, A.H. van Gennip, and R. Berger, A new case of dihydropyrimidine dehydrogenase deficiency, J. Inher. Metab. Dis. 13: 121–124 (1990).
Z. Lu, R. Zhang, and R. B Diasio, Purification and characterization of dihydropyrimidine dehydrogenase from human liver, J. Biol. Chem. 267:17102–17109 (1992).
R. Zhang, Z. Lu, and R. B. Diasio, Quantitation of dihydropyrimidine dehydrogenase (DPD) using a polyclonal antibody to human liver DPD, Proc. Am. Assoc. Cancer. Res. 35:200 (1994).
Z. Lu, R. Zhang, and Diasio, R. B. Genetic polymorphism of dihydropyrimidine dehydrogenase (DPD), the key enzyme in 5-fluorouracil (FUra) catabolism, Clin. Pharm. Ther. 54: 180 (1994).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer Science+Business Media New York
About this chapter
Cite this chapter
Diasio, R.B. et al. (1995). Determination of Dihydropyrimidine Dehydrogenase (DPD) in Fibroblasts of a DPD Deficient Pediatric Patient and Family Members using a Polyclonal Antibody to Human DPD. In: Sahota, A., Taylor, M.W. (eds) Purine and Pyrimidine Metabolism in Man VIII. Advances in Experimental Medicine and Biology, vol 370. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-2584-4_2
Download citation
DOI: https://doi.org/10.1007/978-1-4615-2584-4_2
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6105-3
Online ISBN: 978-1-4615-2584-4
eBook Packages: Springer Book Archive